Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study.

Biccler JL, Glimelius I, Eloranta S, Smeland KB, Brown PN, Jakobsen LH, Frederiksen H, Jerkeman M, Fosså A, Andersson TML, Holte H, Bøgsted M, El-Galaly TC, Smedby KE.

J Clin Oncol. 2019 Feb 6:JCO1801652. doi: 10.1200/JCO.18.01652. [Epub ahead of print]

PMID:
30726176
2.

Estimating the loss of lifetime function using flexible parametric relative survival models.

Jakobsen LH, Andersson TM, Biccler JL, El-Galaly TC, Bøgsted M.

BMC Med Res Methodol. 2019 Jan 28;19(1):23. doi: 10.1186/s12874-019-0661-8.

3.

Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study.

Biccler JL, Eloranta S, de Nully Brown P, Frederiksen H, Jerkeman M, Jørgensen J, Jakobsen LH, Smedby KE, Bøgsted M, El-Galaly TC.

JCO Clin Cancer Inform. 2018 Dec;2:1-13. doi: 10.1200/CCI.18.00025.

4.

Limited value of routine follow-up visits in chronic lymphocytic leukemia managed initially by watch and wait: A North Denmark population-based study.

Nørgaard CH, Søgaard NB, Biccler JL, Pilgaard L, Eskesen MH, Kjartansdottir TH, Bøgsted M, El-Galaly TC.

PLoS One. 2018 Dec 27;13(12):e0208180. doi: 10.1371/journal.pone.0208180. eCollection 2018.

5.

Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG.

Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT, Mikhaeel NG.

Blood. 2019 Jan 17;133(3):237-245. doi: 10.1182/blood-2018-04-843540. Epub 2018 Nov 16.

PMID:
30446493
6.

Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas.

Biccler JL, El-Galaly TC, Bøgsted M, Jørgensen J, de Nully Brown P, Poulsen CB, Starklint J, Juul MB, Christensen JH, Josefsson P, Dessau A, Jakobsen LH.

Leuk Lymphoma. 2018 Nov 14:1-4. doi: 10.1080/10428194.2018.1540044. [Epub ahead of print] No abstract available.

PMID:
30424711
7.

Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.

Baech J, Hansen SM, Lund PE, Soegaard P, Brown PN, Haaber J, Jørgensen J, Starklint J, Josefsson P, Poulsen CB, Juul MB, Torp-Pedersen C, El-Galaly TC.

Br J Haematol. 2018 Dec;183(5):717-726. doi: 10.1111/bjh.15603. Epub 2018 Nov 8.

PMID:
30406945
8.

FDG-PET/CT in the management of lymphomas: current status and future directions.

El-Galaly TC, Villa D, Gormsen LC, Baech J, Lo A, Cheah CY.

J Intern Med. 2018 Oct;284(4):358-376. doi: 10.1111/joim.12813. Epub 2018 Jul 24. Review.

PMID:
29989234
9.

Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study.

Juul MB, Jensen PH, Engberg H, Wehberg S, Dessau-Arp A, Haziri D, Kristensen HB, Baech J, Schurmann L, Clausen MR, Valentin R, Knudsen LM, Munksgaard L, El-Galaly TC, Frederiksen H, Larsen TS.

Eur J Cancer. 2018 Aug;99:86-96. doi: 10.1016/j.ejca.2018.05.006. Epub 2018 Jun 20.

PMID:
29935491
10.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM.

Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Review.

11.

Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study.

Wästerlid T, Biccler JL, Brown PN, Bøgsted M, Enblad G, Mészáros Jørgensen J, Christensen JH, Wahlin BE, Smedby KE, El-Galaly TC, Jerkeman M.

Ann Oncol. 2018 Aug 1;29(8):1882-1883. doi: 10.1093/annonc/mdy184. No abstract available.

PMID:
29790897
12.

Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement.

Chin CK, Tsang E, Mediwake H, Khair W, Biccler J, Hapgood G, Mollee P, Nizich Z, Joske D, Radeski D, Cull G, Villa D, El-Galaly TC, Cheah CY.

Br J Haematol. 2019 Mar;184(5):826-828. doi: 10.1111/bjh.15173. Epub 2018 Apr 20. No abstract available.

PMID:
29676487
13.

Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study.

Nørgaard CH, Jakobsen LH, Gentles AJ, Dybkær K, El-Galaly TC, Bødker JS, Schmitz A, Johansen P, Herold T, Spiekermann K, Brown JR, Klitgaard JL, Johnsen HE, Bøgsted M.

PLoS One. 2018 Mar 7;13(3):e0193249. doi: 10.1371/journal.pone.0193249. eCollection 2018.

14.

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D.

Eur J Cancer. 2018 Apr;93:57-68. doi: 10.1016/j.ejca.2018.01.073. Epub 2018 Feb 21.

PMID:
29477102
15.

Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study.

Biccler JL, Østgård LSG, Severinsen MT, Marcher CW, Møller P, Schöllkopf C, Friis LS, Bøgsted M, Jakobsen LH, El-Galaly TC, Nørgaard JM.

Leukemia. 2018 Oct;32(10):2263-2303. doi: 10.1038/s41375-018-0054-8. Epub 2018 Feb 23. No abstract available.

PMID:
29476132
16.

Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI.

Biccler J, Eloranta S, de Nully Brown P, Frederiksen H, Jerkeman M, Smedby KE, Bøgsted M, El-Galaly TC.

Cancer Med. 2018 Jan;7(1):114-122. doi: 10.1002/cam4.1271. Epub 2017 Dec 13. Erratum in: Cancer Med. 2018 Apr;7(4):1572.

17.

PET/CT for Staging; Past, Present, and Future.

El-Galaly TC, Gormsen LC, Hutchings M.

Semin Nucl Med. 2018 Jan;48(1):4-16. doi: 10.1053/j.semnuclmed.2017.09.001. Epub 2017 Sep 21. Review.

PMID:
29195617
18.

Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.

Cottereau AS, El-Galaly TC, Becker S, Broussais F, Petersen LJ, Bonnet C, Prior JO, Tilly H, Hutchings M, Casasnovas O, Meignan M.

J Nucl Med. 2018 Apr;59(4):589-595. doi: 10.2967/jnumed.117.193946. Epub 2017 Sep 1.

PMID:
28864629
19.

Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission.

El-Galaly TC, Cheah CY.

Leuk Lymphoma. 2018 Apr;59(4):775-777. doi: 10.1080/10428194.2017.1365863. Epub 2017 Aug 22. No abstract available.

PMID:
28828884
20.

Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.

Bech RS, Nielsen KL, Larsen TS, Bentzen HH, Lynggaard LS, Do TH, Braendstrup P, Brady J, Mikhaeel NG, Dybkaer K, Johnsen HE, Jensen P, Bøgsted M, El-Galaly TC.

Br J Haematol. 2018 Jul;182(2):297-301. doi: 10.1111/bjh.14775. Epub 2017 May 23. No abstract available.

PMID:
28542714
21.

Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study.

Cederleuf H, Hjort Jakobsen L, Ellin F, de Nully Brown P, Stauffer Larsen T, Bøgsted M, Relander T, Jerkeman M, El-Galaly TC.

Leuk Lymphoma. 2017 Dec;58(12):2815-2823. doi: 10.1080/10428194.2017.1300888. Epub 2017 Mar 20.

PMID:
28317459
22.

The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.

El-Galaly TC, Villa D, Michaelsen TY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Johnsen HE, Seymour JF, Connors JM, de Nully Brown P, Bøgsted M, Cheah CY.

Eur J Cancer. 2017 Apr;75:195-203. doi: 10.1016/j.ejca.2016.12.029. Epub 2017 Feb 23.

PMID:
28237865
23.

Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study.

Zwarthoed C, El-Galaly TC, Canepari M, Ouvrier MJ, Viotti J, Ettaiche M, Viviani S, Rigacci L, Trentin L, Rusconi C, Luminari S, Cantonetti M, Bolis S, Borra A, Darcourt J, Salvi F, Subocz E, Tajer J, Kulikowski W, Malkowski B, Zaucha JM, Gallamini A.

J Nucl Med. 2017 Aug;58(8):1249-1254. doi: 10.2967/jnumed.116.184218. Epub 2017 Jan 26.

24.

Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission.

Bødker JS, Severinsen MT, El-Galaly TC, Brøndum RF, Laursen MB, Falgreen S, Nyegaard M, Schmitz A, Jakobsen LH, Schönherz AA, Due H, Reinholdt L, Bøgsted M, Dybkær K, Johnsen HE.

Exp Hematol Oncol. 2017 Jan 11;6:3. doi: 10.1186/s40164-016-0063-0. eCollection 2017.

25.

Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study.

Jakobsen LH, Bøgsted M, Brown PN, Arboe B, Jørgensen J, Larsen TS, Juul MB, Schurmann L, Højberg L, Bergmann OJ, Lassen T, Josefsson PL, Jensen P, Johnsen HE, El-Galaly TC.

J Clin Oncol. 2017 Mar;35(7):778-784. doi: 10.1200/JCO.2016.70.0765. Epub 2017 Jan 17.

PMID:
28095160
26.

The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K.

Haematologica. 2016 Dec;101(12):1451-1459. Epub 2016 Nov 10. Review.

27.

Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients.

Bendtsen MD, Munksgaard PS, Severinsen MT, Bekric E, Brieghel C, Nielsen KB, Brown PN, Dybkaer K, Johnsen HE, Bøgsted M, El-Galaly TC.

Eur J Haematol. 2017 Apr;98(4):355-362. doi: 10.1111/ejh.12835. Epub 2017 Jan 31.

PMID:
27893172
28.

R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients.

Svendsen P, Shekhrajka N, Nielsen KL, Vestergaard P, Poulsen MØ, Vistisen AK, Munksgaard PS, Severinsen MT, Jensen P, Johnsen HE, Jakobsen LH, Bøgsted M, Frøkjær JB, El-Galaly TC.

Leuk Lymphoma. 2017 May;58(5):1105-1113. doi: 10.1080/10428194.2016.1233543. Epub 2016 Oct 13.

PMID:
27736260
29.

hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine.

Falgreen S, Ellern Bilgrau A, Brøndum RF, Hjort Jakobsen L, Have J, Lindblad Nielsen K, El-Galaly TC, Bødker JS, Schmitz A, H Young K, Johnsen HE, Dybkær K, Bøgsted M.

PLoS One. 2016 Oct 4;11(10):e0163711. doi: 10.1371/journal.pone.0163711. eCollection 2016.

30.

Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.

El-Galaly TC, Cheah CY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Poulsen MØ, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Bøgsted M, Johnsen HE, Seymour JF, Connors JM, Brown PD, Villa D.

Br J Haematol. 2016 Dec;175(5):876-883. doi: 10.1111/bjh.14325. Epub 2016 Sep 29.

PMID:
27681999
31.

The Danish National Lymphoma Registry: Coverage and Data Quality.

Arboe B, El-Galaly TC, Clausen MR, Munksgaard PS, Stoltenberg D, Nygaard MK, Klausen TW, Christensen JH, Gørløv JS, Brown Pde N.

PLoS One. 2016 Jun 23;11(6):e0157999. doi: 10.1371/journal.pone.0157999. eCollection 2016.

32.

Characterization of memory B cells from thymus and its impact for DLBCL classification.

Bergkvist KS, Nørgaard MA, Bøgsted M, Schmitz A, Nyegaard M, Gaihede M, Bæch J, Grønholdt ML, Jensen FS, Johansen P, Urup T, El-Galaly TC, Madsen J, Bødker JS, Dybkær K, Johnsen HE.

Exp Hematol. 2016 Oct;44(10):982-990.e11. doi: 10.1016/j.exphem.2016.06.001. Epub 2016 Jun 11.

PMID:
27297329
33.

miR-155 as a Biomarker in B-Cell Malignancies.

Due H, Svendsen P, Bødker JS, Schmitz A, Bøgsted M, Johnsen HE, El-Galaly TC, Roug AS, Dybkær K.

Biomed Res Int. 2016;2016:9513037. doi: 10.1155/2016/9513037. Epub 2016 May 16. Review.

34.

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.

Cheah CY, Bröckelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA.

Am J Hematol. 2016 Sep;91(9):894-9. doi: 10.1002/ajh.24429. Epub 2016 Jun 20.

35.

The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study.

Alzahrani M, El-Galaly TC, Hutchings M, Hansen JW, Loft A, Johnsen HE, Iyer V, Wilson D, Sehn LH, Savage KJ, Connors JM, Gascoyne RD, Johansen P, Clasen-Linde E, Brown P, Villa D.

Ann Oncol. 2016 Jun;27(6):1095-9. doi: 10.1093/annonc/mdw137. Epub 2016 Mar 21.

PMID:
27002106
36.

Blood on the tracks - toward precision medicine.

Johnsen HE, El-Galaly TC, Dybkær K, Bøgsted M.

Leuk Lymphoma. 2016 Aug;57(8):1753-4. doi: 10.3109/10428194.2016.1154962. Epub 2016 Mar 21. No abstract available.

PMID:
26998891
37.

Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre Study.

Mylam KJ, Michaelsen TY, Hutchings M, Jacobsen Pulczynski E, Pedersen LM, Braendstrup P, Gade IL, Eberlein TR, Gang AO, Bøgsted M, Brown PN, El-Galaly TC.

Br J Haematol. 2017 Feb;176(4):671-673. doi: 10.1111/bjh.13988. Epub 2016 Feb 23. No abstract available.

PMID:
26913572
38.

No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.

Jakobsen LH, Hutchings M, de Nully Brown P, Linderoth J, Mylam KJ, Molin D, Johnsen HE, Bøgsted M, Jerkeman M, El-Galaly TC.

Br J Haematol. 2016 Apr;173(2):236-44. doi: 10.1111/bjh.13943. Epub 2016 Feb 5.

PMID:
26846879
39.

Reply to H.J adams et al: "Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?".

El-Galaly TC, Hutchings M, Villa D.

Am J Hematol. 2016 Feb;91(2):E2-3. doi: 10.1002/ajh.24239. No abstract available.

40.

Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.

El-Galaly TC, Jakobsen LH, Hutchings M, de Nully Brown P, Nilsson-Ehle H, Székely E, Mylam KJ, Hjalmar V, Johnsen HE, Bøgsted M, Jerkeman M.

J Clin Oncol. 2015 Dec 1;33(34):3993-8. doi: 10.1200/JCO.2015.62.0229. Epub 2015 Oct 5.

PMID:
26438115
41.

The application of human phase 0 microdosing trials: A systematic review and perspectives.

Svendsen P, El-Galaly TC, Dybkær K, Bøgsted M, Laursen MB, Schmitz A, Jensen P, Johnsen HE.

Leuk Lymphoma. 2016;57(6):1281-90. doi: 10.3109/10428194.2015.1101097. Epub 2015 Nov 16. Review.

PMID:
26428262
42.

To maintain or not, that is the question.

Jensen P, Bendtsen MD, Johnsen HE, Bøgsted M, El-Galaly TC.

Br J Haematol. 2016 Jul;174(2):321-2. doi: 10.1111/bjh.13761. Epub 2015 Sep 25. No abstract available.

PMID:
26403171
43.

Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.

El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D, de Nully Brown P, Loft A, Iyer V, Johnsen HE, Savage KJ, Connors JM, Hutchings M.

Am J Hematol. 2015 Nov;90(11):1041-6. doi: 10.1002/ajh.24169.

44.

Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.

El-Galaly TC, Pedersen MB, Hutchings M, Mylam KJ, Madsen J, Gang AO, Bøgsted M, de Nully Brown P, Loft A, Nielsen AL, Hendel HW, Iyer V, Gormsen LC.

Am J Hematol. 2015 Nov;90(11):975-80. doi: 10.1002/ajh.24128. Epub 2015 Aug 14.

45.

Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.

Falgreen S, Dybkær K, Young KH, Xu-Monette ZY, El-Galaly TC, Laursen MB, Bødker JS, Kjeldsen MK, Schmitz A, Nyegaard M, Johnsen HE, Bøgsted M.

BMC Cancer. 2015 Apr 8;15:235. doi: 10.1186/s12885-015-1237-6.

46.

Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.

Dybkær K, Bøgsted M, Falgreen S, Bødker JS, Kjeldsen MK, Schmitz A, Bilgrau AE, Xu-Monette ZY, Li L, Bergkvist KS, Laursen MB, Rodrigo-Domingo M, Marques SC, Rasmussen SB, Nyegaard M, Gaihede M, Møller MB, Samworth RJ, Shah RD, Johansen P, El-Galaly TC, Young KH, Johnsen HE.

J Clin Oncol. 2015 Apr 20;33(12):1379-88. doi: 10.1200/JCO.2014.57.7080. Epub 2015 Mar 23.

47.

A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait.

El-Galaly TC, Bilgrau AE, de Nully Brown P, Mylam KJ, Ahmad SA, Pedersen LM, Gang AO, Bentzen HH, Juul MB, Bergmann OJ, Pedersen RS, Nielsen BJ, Johnsen HE, Dybkaer K, Bøgsted M, Hutchings M.

Br J Haematol. 2015 May;169(3):435-44. doi: 10.1111/bjh.13316. Epub 2015 Feb 23.

PMID:
25709094
48.

Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies.

El-Galaly TC, Hutchings M.

Cancer Treat Res. 2015;165:125-46. doi: 10.1007/978-3-319-13150-4_5. Review.

PMID:
25655608
49.

Circulating tumor necrosis factor-α and YKL-40 level is associated with remission status following salvage therapy in relapsed non-Hodgkin lymphoma.

El-Galaly TC, Bilgrau AE, Gaarsdal E, Klausen TW, Pedersen LM, Nielsen KR, Bæch J, Bøgsted M, Dybkær K, Johansen JS, Johnsen HE.

Leuk Lymphoma. 2015;56(8):2476-8. doi: 10.3109/10428194.2014.1001984. Epub 2015 Feb 24. No abstract available.

PMID:
25563560
50.

Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma.

Laursen MB, Falgreen S, Bødker JS, Schmitz A, Kjeldsen MK, Sørensen S, Madsen J, El-Galaly TC, Bøgsted M, Dybkær K, Johnsen HE; Myeloma Stem Cell Network.

Exp Hematol. 2014 Nov;42(11):927-38. doi: 10.1016/j.exphem.2014.07.263. Epub 2014 Jul 27. Review.

PMID:
25072621

Supplemental Content

Loading ...
Support Center